The histone deacetylase inhibitor sodium butyrate promotes cell death and differentiation and reduces neurosphere formation in human medulloblastoma cells

Molecular Neurobiology

Volumn 48, Issue 3, 2013, Pages 533-543

  Nör, Carolina ^a,b,c   Sassi, Felipe A ^a,b,c   De Farias, Caroline Brunetto ^a,c   Schwartsmann, Gilberto ^a,b,c   Abujamra, Ana Lucia ^a,c   Lenz, Guido ^b   Brunetto, Algemir Lunardi ^a,b,c   Roesler, Rafael ^a,b,c  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c National Institute for Translational Medicine   (Brazil)

Author keywords

Brain cancer; Brain tumor stem cell; Chromatin; Epigenetics; Histone deacetylase; Medulloblastoma

Indexed keywords

BUTYRIC ACID; ETOPOSIDE; MESSENGER RNA;

CELL COUNT; CELL DEATH; CELL DIFFERENTIATION; CELL SURVIVAL; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INHIBITION KINETICS; MEDULLOBLASTOMA; NERVE CELL DIFFERENTIATION; REVIEW; TUMOR CELL; TUMOR CELL LINE;

BRAIN NEOPLASMS; BUTYRIC ACID; CELL DEATH; CELL DIFFERENTIATION; CELL SURVIVAL; ETOPOSIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; MEDULLOBLASTOMA; RNA, MESSENGER; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; TUMOR STEM CELL ASSAY;

EID: 84887994629     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-013-8441-7     Document Type: Review

References (58)

1. Crawford JR, MacDonald TJ, Packer RJ (2007) Medulloblastoma in childhood: New biological advances. Lancet Neurol 6:1073-1085
2. Polkinghorn WR, Tarbell NJ (2007) Medulloblastoma: Tumorigenesis, current clinical paradigm, and efforts to improve risk stratification. Nat Clin Pract Oncol 4:295-304
3. Rossi A, Caracciolo V, Russo G, Reiss K, Giordano A (2008) Medulloblastoma: From molecular pathology to therapy. Clin Cancer Res 14:971-976
4. Sutter R, Shakhova O, Bhagat H, Behesti H, Sutter C, Penkar S, Santuccione A, Bernays R, Heppner FL, Schüller U, Grotzer M, Moch H, Schraml P, Marino S (2010) Cerebellar stem cells act as medulloblastoma- initiating cells in a mouse model and a neural stem cell signature characterizes a subset of human medulloblastomas. Oncogene 29:1845-1856
5. Northcott PA, Jones DT, Kool M, Robinson GW, Gilbertson RJ, Cho YJ, Pomeroy SL, Korshunov A, Lichter P, Taylor MD, Pfister SM (2012) Medulloblastomics: The end of the beginning. Nat Rev Cancer 12:818-834
6. Wang J, Wechsler-Reya RJ (2013) The role of stem cells and progenitors in the genesis of medulloblastoma. Exp Neurol. doi: 10.1016/j.expneurol.2012.11. 014
7. Fan X, Eberhart CG (2008) Medulloblastoma stem cells. J Clin Oncol 26:2821-2827
8. Flores DG, Ledur PF, Abujamra AL, Brunetto AL, Schwartsmann G, Lenz G, Roesler R (2009) Cancer stem cells and the biology of brain tumors. Curr Stem Cell Res Ther 4:306-313
9. Hadjipanayis CG, Van Meir EG (2009) Brain cancer propagating cells: Biology, genetics and targeted therapies. Trends Mol Med 15:519-530
10. Kouzarides T (2007) Chromatin modifications and their function. Cell 128:693-705
11. Jones DT, Jäger N, Kool M, Zichner T, Hutter B, Sultan M, Cho YJ, Pugh TJ, Hovestadt V, Stütz AM, Rausch T, Warnatz HJ, Ryzhova M, Bender S, Sturm D, Pleier S, Cin H, Pfaff E, Sieber L, Wittmann A, Remke M, Witt H, Hutter S, Tzaridis T, Weischenfeldt J, Raeder B, Avci M, Amstislavskiy V, Zapatka M, Weber UD, Wang Q, Lasitschka B, Bartholomae CC, Schmidt M, von Kalle C, Ast V, Lawerenz C, Eils J, Kabbe R, Benes V, van Sluis P, Koster J, Volckmann R, Shih D, Betts MJ, Russell RB, Coco S, Tonini GP, Schüller U, Hans V, Graf N, Kim YJ, Monoranu C, Roggendorf W, Unterberg A, Herold-Mende C, Milde T, Kulozik AE, von Deimling A, Witt O, Maass E, Rössler J, Ebinger M, Schuhmann MU, Frühwald MC, Hasselblatt M, Jabado N, Rutkowski S, von Bueren AO, Williamson D, Clifford SC, McCabe MG, Collins VP, Wolf S, Wiemann S, Lehrach H, Brors B, Scheurlen W, Felsberg J, Reifenberger G, Northcott PA, Taylor MD, Meyerson M, Pomeroy SL, Yaspo ML, Korbel JO, Korshunov A, Eils R, Pfister SM, Lichter P (2012) Dissecting the genomic complexity underlying medulloblastoma. Nature 488:100-105
12. Northcott PA, Nakahara Y, Wu X, Feuk L, Ellison DW, Croul S, Mack S, Kongkham PN, Peacock J, Dubuc A, Ra YS, Zilberberg K, McLeod J, Scherer SW, Sunil Rao J, Eberhart CG, Grajkowska W, Gillespie Y, Lach B, Grundy R, Pollack IF, Hamilton RL, Van Meter T, Carlotti CG, Boop F, Bigner D, Gilbertson RJ, Rutka JT, Taylor MD (2009) Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet 41:465-472
13. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769-784
14. Leder A, Orkin S, Leder P (1975) Differentiation of erythroleukemic cells in the presence of inhibitors of DNA synthesis. Science 190:893-894
15. Riggs MG, Whittaker RG, Neumann JR, Ingram VM (1977) n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature 268:462-464
16. Candido EP, Reeves R, Davie JR (1978) Sodium butyrate inhibits histone deacetylation in cultured cells. Cell 14:105-113
17. Bhalla KN (2005) Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 23:3971-3993
18. Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38-51
19. Sonnemann J, Kumar KS, Heesch S, Müller C, Hartwig C, Maass M, Bader P, Beck JF (2006) Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells. Int J Oncol 28:755-766
20. Furchert SE, Lanvers-Kaminsky C, Juürgens H, Jung M, Loidl A, Frühwald MC (2007) Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int J Cancer 120:1787-1794
21. Kumar KS, Sonnemann J, le Hong TT, Buurman C, Adler F, Maass M, Völker U, Beck JF (2007) Histone deacetylase inhibitors, but not vincristine, cooperate with radiotherapy to induce cell death in medulloblastoma. Anticancer Res 27:465-470
22. Häcker S, Karl S, Mader I, Cristofanon S, Schweitzer T, Krauss J, Rutkowski S, Debatin KM, Fulda S (2011) Histone deacetylase inhibitors prime medulloblastoma cells for chemotherapy-induced apoptosis by enhancing p53-dependent Bax activation. Oncogene 30:2275-2281
23. Sonnemann J, Trommer N, Becker S, Wittig S, Grauel D, Palani CD, Beck JF (2012) Histone deacetylase inhibitor-mediated sensitization to TRAIL-induced apoptosis in childhood malignancies is not associated with upregulation of TRAIL receptor expression, but with potentiated caspase-8 activation. Cancer Biol Ther 13:417-424
24. Tang Y, Yacoub A, Hamed HA, Poklepovic A, Tye G, Grant S, Dent P (2012) Sorafenib and HDAC inhibitors synergize to kill CNS tumor cells. Cancer Biol Ther 13:567-574
25. Li XN, Shu Q, Su JM, Perlaky L, Blaney SM, Lau CC (2005) Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Mol Cancer Ther 4:1912-1922
26. Nör C, de Farias CB, Abujamra AL, Schwartsmann G, Brunetto AL, Roesler R (2011) The histone deacetylase inhibitor sodium butyrate in combination with brain-derived neurotrophic factor reduces the viability of DAOY human medulloblastoma cells. Childs Nerv Syst 27:897-901
27. Milde T, Kleber S, Korshunov A, Witt H, Hielscher T, Koch P, Kopp HG, Jugold M, Deubzer HE, Oehme I, Lodrini M, Gröne HJ, Benner A, Brüstle O, Gilbertson RJ, von Deimling A, Kulozik AE, Pfister SM, Martin-Villalba A, Witt O (2011) A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat. Acta Neuropathol 122:637-650
28. Asklund T, Kvarnbrink S, Holmlund C, Wibom C, Bergenheim T, Henriksson R, Hedman H (2012) Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors. Anticancer Res 32:2407-2413
29. Sassi FA, Brunetto AL, Schwartsmann G, Roesler R, Abujamra AL (2012) Glioma revisited: From neurogenesis and cancer stem cells to the epigenetic regulation of the niche. J Oncol 2012:537861
30. Schmidt AL, de Farias CB, Abujamra AL, Kapczinski F, Schwartsmann G, Brunetto AL, Roesler R (2010) BDNF and PDE4, but not the GRPR, regulate viability of human medulloblastoma cells. J Mol Neurosci 40:303-310
31. Franken NAP, Rodermond HM, Stap J, Jaap Haveman J, van Bree C (2006) Clonogenic assay of cells in vitro. Nat Protocols 1:2315-2319
32. Pastrana E, Silva-Vargas V, Doetsch F (2011) Eyes wide open: A critical review of sphere-formation as an assay for stem cells. Cell Stem Cell 8:486-498
33. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821-5828
34. Annabi B, Rojas-Sutterlin S, Laflamme C, Lachambre MP, Rolland Y, Sartelet H, Béliveau R (2008) Tumor environment dictates medulloblastoma cancer stem cell expression and invasive phenotype. Mol Cancer Res 6:907-916
35. Sanchez-Diaz PC, Burton TL, Burns SC, Hung JY, Penalva LO (2008) Musashi1 modulates cell proliferation genes in the medulloblastoma cell line Daoy. BMC Cancer 8:280
36. Korur S, Huber RM, Sivasankaran B, Petrich M, Morin P Jr, Hemmings BA, Merlo A, Lino MM (2009) GSK3beta regulates differentiation and growth arrest in glioblastoma. PLoS One 4:7443
37. Huang X, Ketova T, Litingtung Y, Chiang C (2010) Isolation, enrichment, and maintenance of medulloblastoma stem cells. J Vis Exp (43): doi: 10.3791/2086
38. Bai RY, Staedtke V, Lidov HG, Eberhart CG, Riggins GJ (2012) OTX2 represses myogenic and neuronal differentiation in medulloblastoma cells. Cancer Res 72:5988-6001
39. Rogers HA, Sousa S, Salto C, Arenas E, Coyle B, Grundy RG (2012) WNT/β-catenin pathway activation in Myc immortalised cerebellar progenitor cells inhibits neuronal differentiation and generates tumours resembling medulloblastoma. Br J Cancer 107:1144-1152
40. Li XN, Parikh S, Shu Q, Jung HL, Chow CW, Perlaky L, Leung HC, Su J, Blaney S, Lau CC (2004) Phenylbutyrate and phenylacetate induce differentiation and inhibit proliferation of human medulloblastoma cells. Clin Cancer Res 10:1150-1159
41. Hagihara H, Ohira K, Toyama K, Miyakawa T (2011) Expression of the AMPA receptor subunits GluR1 and GluR2 is associated with granule cell maturation in the dentate gyrus. Front Neurosci 5:100
42. Canettieri G, Di Marcotullio L, Greco A, Coni S, Antonucci L, Infante P, Pietrosanti L, De Smaele E, Ferretti E, Miele E, Pelloni M, De Simone G, Pedone EM, Gallinari P, Giorgi A, Steinkühler C, Vitagliano L, Pedone C, Schinin ME, Screpanti I, Gulino A (2010) Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation. Nat Cell Biol 12:132-142
43. Canettieri G, Di Marcotullio L, Coni S, Greco A, Gulino A (2010) Turning off the switch in medulloblastoma: The inhibitory acetylation of an oncogene. Cell Cycle 9:2047-2048
44. Di Marcotullio L, Ferretti E, De Smaele E, Screpanti I, Gulino A (2006) Suppressors of hedgehog signaling: Linking aberrant development of neural progenitors and tumorigenesis. Mol Neurobiol 34:193-204
45. Schmidt AL, Brunetto AL, Schwartsmann G, Roesler R, Abujamra AL (2010) Recent therapeutic advances for treating medulloblastoma: Focus on new molecular targets. CNS Neurol Disord Drug Targets 9:335-348
46. Di Marcotullio L, Ferretti E, De Smaele E, Argenti B, Mincione C, Zazzeroni F, Gallo R, Masuelli L, Napolitano M, Maroder M, Modesti A, Giangaspero F, Screpanti I, Alesse E, Gulino A (2004) REN(KCTD11) is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma. Proc Natl Acad Sci U S A 101:10833-10838
47. De Smaele E, Di Marcotullio L, Moretti M, Pelloni M, Occhione MA, Infante P, Cucchi D, Greco A, Pietrosanti L, Todorovic J, Coni S, Canettieri G, Ferretti E, Bei R, Maroder M, Screpanti I, Gulino A (2011) Identification and characterization of KCASH2 and KCASH3, 2 novel Cullin3 adaptors suppressing histone deacetylase and Hedgehog activity in medulloblastoma. Neoplasia 13:374-385
48. He XM, Skapek SX, Wikstrand CJ, Friedman HS, Trojanowski JQ, Kemshead JT, Coakham HB, Bigner SH, Bigner DD (1989) Phenotypic analysis of four human medulloblastoma cell lines and transplantable xenografts. J Neuropathol Exp Neurol 48:48-68
49. Barrett LE, Granot Z, Coker C, Iavarone A, Hambardzumyan D, Holland EC, Nam HS, Benezra R (2012) Self-renewal does not predict tumor growth potential in mouse models of high-grade glioma. Cancer Cell 21:11-24
50. Read TA, Wechsler-Reya RJ (2012) Spheres without influence: Dissociating in vitro self-renewal from tumorigenic potential in glioma. Cancer Cell 21:1-3
51. Rodini CO, Suzuki DE, Saba-Silva N, Cappellano A, de Souza JE, Cavalheiro S, Toledo SR, Okamoto OK (2012) Expression analysis of stem cell-related genes reveal OCT4 as a predictor of poor clinical outcome in medulloblastoma. J Neurooncol 106:71-79
52. Wang X, Ge J, Wang K, Qian J, Zou Y (2006) Evaluation of MTT assay for measurement of emodin-induced cytotoxicity. Assay Drug Dev Technol 4:203-237
53. van Meerloo J, Kaspers GJ, Cloos J (2011) Cell sensitivity assays: The MTT assay. Methods Mol Biol 731:237-245
54. dos Santos MP, Schwartsmann G, Roesler R, Brunetto AL, Abujamra AL (2009) Sodium butyrate enhances the cytotoxic effect of antineoplastic drugs in human lymphoblastic T-cells. Leuk Res 33:218-221
55. Tsai SC, Valkov N, Yang WM, Gump J, Sullivan D, Seto E (2000) Histone deacetylase interacts directly with DNA topoisomerase II. Nat Genet 26:349-353
56. Hande KR (1998) Etoposide: Four decades of development of a topoisomerase II inhibitor. Eur J Cancer 34:1514-1521
57. Geyer JR, Sposto R, Jennings M, Boyett JM, Axtell RA, Breiger D, Broxson E, Donahue B, Finlay JL, Goldwein JW, Heier LA, Johnson D, Mazewski C, Miller DC, Packer R, Puccetti D, Radcliffe J, Tao ML, Shiminski-Maher T; Children's Cancer Group (2005) Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: A report from the Children's Cancer Group. J Clin Oncol 23:7621-7631
58. Ruggiero A, Rizzo D, Attinà G, Lazzareschi I, Mastrangelo S, Maurizi P, Migliorati R, Bertolini P, Pastore M, Colosimo C, Riccardi R (2010) Phase I study of temozolomide combined with oral etoposide in children with recurrent or progressive medulloblastoma. Eur J Cancer 46:2943-2949